Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt: 2020-2025

Historic Non-Current Debt for Aytu Biopharma (AYTU) over the last 5 years, with Sep 2025 value amounting to $10.4 million.

  • Aytu Biopharma's Non-Current Debt rose 0.16% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 0.16%. This contributed to the annual value of $10.9 million for FY2025, which is 0.17% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Non-Current Debt is $10.4 million, which was down 4.11% from $10.9 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Non-Current Debt peaked at $15.0 million during Q4 2023, and registered a low of $129,000 during Q4 2021.
  • Moreover, its 3-year median value for Non-Current Debt was $10.9 million (2024), whereas its average is $11.8 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first tumbled by 98.70% in 2021, then spiked by 11,165.89% in 2022.
  • Aytu Biopharma's Non-Current Debt (Quarterly) stood at $129,000 in 2021, then skyrocketed by 11,165.89% to $14.5 million in 2022, then grew by 3.06% to $15.0 million in 2023, then crashed by 33.35% to $10.0 million in 2024, then increased by 0.16% to $10.4 million in 2025.
  • Its Non-Current Debt was $10.4 million in Q3 2025, compared to $10.9 million in Q2 2025 and $9.5 million in Q1 2025.